WED-511 FIB-4 for identifying chronic liver disease patients requiring HCC surveillance

Jan Embacher(Medical University of Vienna), Mattias Mandorfer(Medical University of Vienna), Benedikt Simbrunner(Medical University of Vienna), Lukas Hartl(Medical University of Vienna), Bernhard Scheiner(Medical University of Vienna), Matthias Pinter(Medical University of Vienna), Michael Trauner(Medical University of Vienna), Georg Semmler(University of Southern Denmark), Nina Dominik(Medical University of Vienna), Thomas Reiberger(ERN GUARD-Heart), Benedikt Hofer(Austrian Academy of Sciences), Mathias Jachs(Medical University of Vienna), Christian Sebesta(Donauspital), Lorenz Balcar(Medical University of Vienna), Georg Kramer(Medical University of Vienna), Paul Thöne(Medical University of Vienna)
Journal of Hepatology
May 1, 2025
10.1016/s0168-8278(25)01723-4
Cited by 1

Related Papers

NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score
|Journal of Hepatology|2021|309
Cancer and liver cirrhosis: implications on prognosis and management
|ESMO Open|2016|287
Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation
|Journal of Hepatology|2024|239